5IFO

X-ray structure of HSA-Myr-KP1019

5IFO の概要

• エントリーDOI: 10.2210/pdb5ifo/pdb
• 分子名称: Serum albumin, RUTHENIUM ION, MYRISTIC ACID, ... (4 entities in total)
• 機能のキーワード: complex, anticancer drug, serum protein, transport protein
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 68143.58

構造登録者

Bijelic, A.,Theiner, S.,Keppler, B.K.,Rompel, A. (登録日: 2016-02-26, 公開日: 2016-06-01, 最終更新日: 2024-01-10)

主引用文献

Bijelic, A.,Theiner, S.,Keppler, B.K.,Rompel, A.
X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.
J.Med.Chem., 59:5894-5903, 2016

PubMed Abstract: Ruthenium(III) complexes are promising candidates for anticancer drugs, especially the clinically studied indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) and its analogue sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (NKP-1339). Several studies have emphasized the likely role of human serum proteins in the transportation and accumulation of ruthenium(III) complexes in tumors. Therefore, the interaction between KP1019 and human serum albumin was investigated by means of X-ray crystallography and inductively coupled plasma mass spectrometry (ICP-MS). The structural data unambiguously reveal the binding of two ruthenium atoms to histidine residues 146 and 242, which are both located within well-known hydrophobic binding pockets of albumin. The ruthenium centers are octahedrally coordinated by solvent molecules revealing the dissociation of both indazole ligands from the ruthenium-based drug. However, a binding mechanism is proposed indicating the importance of the indazole ligands for binding site recognition and thus their indispensable role for the binding of KP1019.

PubMed: 27196130
DOI: 10.1021/acs.jmedchem.6b00600

実験手法

X-RAY DIFFRACTION (3.2 Å)